|
Latest Medical & OCAN News Articles
The Ovarian Cancer Alliance of Nevada wants to help extend your knowledge by keeping you informed about the latest happenings in this area of your health. They consist of articles not only about medical breakthroughs, but of success, hope, and actions. The following links are to articles for the current month, that have appeared in newspapers, publications and TV stations from sources throughout both the U.S. and world wide, and are available with on-line editions. Each listing has a short opening paragraph of the article. The listing of the links are by date published, with the most recent found listed first.
For archived articles prior to the current calendar month, please see: Ovarian Cancer Archived News
Febuary 2007
Feb 26, 2007 - "Med India",
Wrong Belief About Ovarian Cancer
According to a latest survey half of Australian women are under the impression that ovarian cancer can be detected by pap smear test. The National Breast Cancer Centre felt that this wrong notion is more dangerous to the lives of many women.
Feb 22, 2007 - "Cancer News", Dallas, TX
Painkiller reduces risk of ovarian cancer with risk of its own
According to Athens University researchers, taking paracetamol daily could reduce, by 30 percent, the risk of ovarian cancer. But the researchers warn that it might not be the best choice in cancer prevention. Why? Because taking paracetamol can lead to serious liver and kidney damage. The words acetaminophen and paracetamol both come from the chemical names for the compound N-acetyl-para-aminophenol and para-acetyl-amino-phenol. In North America, paracetamol is sold in generic form or under a number of trade names like Tylenol, Anacin-3 and Datril. In Europe, it is known as Panadol.
Feb 22, 2007 - "Cancer News", Dallas, TX
Exercise does not lower ovarian cancer risks
Exercise and physical activity should benefit all areas of health, including cancer prevention, but in the case of ovarian cancer, researchers are stating that it doesn't seem to make a difference in the number of women who go on to be diagnosed with ovarian cancer. Karolinska Institute in Stockholm researchers tracked 96,000 women from Norway and Sweden for over a decade, noting levels of physical activity at different points in each woman's life to ovarian cancer diagnosis among all women in the group, and found the risk of developing ovarian cancer was the same for women who were very physically active compared to women who did not move around too much.
Feb 21, 2007 - "Public Med",
Prevention and early detection of ovarian cancer: mission impossible?
Epithelial ovarian cancer is neither a common nor a rare disease. In the United States, the prevalence of ovarian cancer in postmenopausal women (1 in 2,500) significantly affects strategies for prevention and detection.
Feb 21, 2007 - " MedlinePlus",
Genomic Approach Offers Individualized Cancer Treatment
A genomic approach to evaluating tumors can allow individualized treatment of women with advanced-stage ovarian cancer, according to a report in the February 10th Journal of Clinical Oncology. The clinical heterogeneity of ovarian cancer contributes to the variable response to chemotherapy, the authors explain, and no single gene marker reliably predicts response to therapy and outcomes.
Feb 20, 2007 - "Advantage Business Media", Morris Plains,NJ
Treating Ovarian Cancer with Surgical Implant
An advanced drug delivery system to treat ovarian cancer, PoLi, developed at the University of Toronto, is a small hydrogel infused with cancer-killing drugs that is surgically implanted to kill cancer cells while minimizing the side effects of chemotherapy.
Feb 19, 2007 - " MedlinePlus",
Pregnancy and Oral Contraceptives Offer Strongest Anti-Ovarian Cancer Effects
Compared with other anovulatory factors, pregnancy and oral contraceptive are associated with the lowest risk of developing ovarian cancer, according to a report in the January issue of the American Journal of Obstetrics and Gynecology.
Feb 17, 2007 - "Public Med",
Principles and practice of intraperitoneal chemotherapy for ovarian cancer
Intraperitoneal (IP) chemotherapy has been studied for years to improve the survival of patients with ovarian cancer. Recently, the result of Gynecologic Oncology Group 172 trial comparing IP versus intravenous administration of cisplatin-based chemotherapy was published, demonstrating the improvement of survival benefit in favor of the IP arm.
Feb 17, 2007 - "Science Daily",
Computer Tool Helps Pinpoint Risky Gene Mutations, Predict Cancer Cases
Certain cancer risks can be passed down through families, the result of tiny changes in a family's genetic code. But not all genetic changes are deadly. To help medical counselors and physicians identify the mutations that pose the greatest health risks, researchers at four institutions, including Johns Hopkins, have developed and validated a new computer tool
Feb 16, 2007 - "Bloomberg, L.P.", New York City, NY
Schering-Plough Cites Positive Results From Caelyx Against Ovarian Cancer
Schering-Plough Corp. said a published study found that combination therapy using the drug Caelyx and platinum was highly effective against ovarian cancer that had been previously treated. The overall response rate of 63 percent and complete response rate of 38 percent as well as survival rates ``are promising and support the need for further evaluation'' of the combined treatment, the company said today in a statement distributed by PR Newswire.
Feb 14, 2007 - "National Cancer Institute",
Impact of Intraperitoneal Chemotherapy on Quality of Life During Ovarian Cancer Treatment
Women with ovarian cancer treated with a combination of intraperitoneal (IP) and intravenous (IV) chemotherapy reported more side effects and a lower quality of life during their treatment compared to women receiving IV chemotherapy only. However, at the end of one year only neurological symptoms (such as tingling in the hands and feet) remained worse for the IV/IP chemotherapy group; otherwise, the women’s quality of life was about the same.
Feb 13, 2007 - "The Wall Street Journal", NYC, NY
Cancer Patients Gain Say in Drug Approvals
A cancer drug's effectiveness has long been measured in two important ways: whether it shrinks a tumor and whether it extends patients' lives. But researchers and regulators are paying increasing attention to another criterion: how a patient feels while taking the medicine.
Feb 07, 2007 - "The Wichita Eagle", Wichita, KS
Cutting risk of ovarian cancer may mean taking other risks
Every year, an estimated 300,000 healthy women undergo a surgical procedure to lower their risk for a rare cancer, but new research shows it actually increases their risk of dying from other causes.
Feb 06, 2007 - "Science Daily", Chevy Chase, MD
Biodegradable Implant Holds Promise As Ovarian Cancer Treatment
A collaborative effort between researchers at the Leslie Dan Faculty of Pharmacy has resulted in an advanced drug delivery system for the treatment of ovarian cancer. PoLi, developed by Professors Micheline Piquette-Miller and Christine Allen, is a surgical implant that effectively kills cancer cells while minimizing the side effects of chemotherapy.
Feb 06, 2007 - "The Washington Post", Washington, DC
How Much Do You Want -- or Need -- to Know?
Four times, I have been diagnosed with life-threatening diseases. Each time, the news stopped me cold; it landed me in a hospital; it forced me to rearrange my life and rethink my responsibilities while my body was battered by drugs and surgery.
|
|